Literature DB >> 33083815

Influenza vaccination in chronic inflammatory arthritis undergoing immunosuppressive treatments: temporal trend and factors of adherence.

Luca Quartuccio1, Alen Zabotti1, Tolinda Gallo2, Salvatore De Vita1, Francesca Valent3.   

Abstract

OBJECTIVES: To verify the level of adherence to the influenza vaccination program in a population of patients suffering from RA, PsA or AS undergoing immunosuppressive treatment.
METHODS: Administrative databases from the Regional Health Information System of Friuli Venezia Giulia (FVG), Italy, were used. Subjects were residents in FVG, suffered from chronic inflammatory arthritis and had at least one prescription for a DMARD in the 9 months before the start of the vaccination season (from 1 October to 31 December). The observation ranged from 2006 to 2018. Logistic regression was used to assess the association between vaccination and the patient's characteristics in the 2018-2019 influenza season.
RESULTS: Overall, vaccination adherence decreased from the highest value of 35.7% (662/1853) in 2006 to the lowest value of 25.3% (926/3663) in 2014; in people ≥65 years of age it also decreased over time from 61.6% (577/936) in 2008 to 43.9% (701/1595) in the 2014. By logistic analysis on the 2018-2019 season, which included 4460 patients, older subjects were more likely to be vaccinated [people 65-74 years, odds ratio (OR) 4.58 (95% CI 3.72, 5.64); people 75-84 years, OR 6.47 (95% CI 5.04, 8.32); both vs <65] as were those with diabetes [OR 1.66 (95% CI 1.05, 2.64)]. Treatment with a biologic agent alone [OR 0.64 (95% CI 0.52, 0.80)] and RA diagnosis [OR 0.69 (95% CI 0.51, 0.93)] were associated with lower adherence.
CONCLUSION: Influenza vaccination adherence is alarmingly low in a population at higher risk of infectious complications, in particular in elderly patients.
© The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  arthritis; biologic agent; influenza; small molecules; vaccine

Year:  2021        PMID: 33083815     DOI: 10.1093/rheumatology/keaa454

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  1 in total

1.  High T-cell response rate after COVID-19 vaccination in belimumab and rituximab recipients.

Authors:  Martina Fabris; Ginevra De Marchi; Rossana Domenis; Federica Caponnetto; Silvia Guella; Chiara Dal Secco; Nicola Cabas; Salvatore De Vita; Antonio Paolo Beltrami; Francesco Curcio; Luca Quartuccio
Journal:  J Autoimmun       Date:  2022-04-11       Impact factor: 14.511

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.